CNS Pharmaceuticals Inc. CNSP Archives - Page 18 of 22

MondayFeb 22, 2021 2:55 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Eyes Transformation as Berubicin Becomes Subject of Active Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. The company’s pipeline includes Berubicin for the treatment of patients with glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. CNS is currently focused on the development and clinical trials of Berubicin for GBM, as well as the potential of addressing other central nervous system malignancies. “The company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our…

ThursdayFeb 18, 2021 12:52 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Key Milestone, Progress Toward Collaborative Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (8SV1.F) (“WPD”), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that WPD received a positive opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland for its planned upcoming Berubicin clinical trial in adults with Glioblastoma Multiforme (“GBM”) under the WPD-201 Clinical Trial Protocol. CNS Pharmaceuticals has received study level approval from the Central IRB for the CNS-201 Clinical Trial Protocol. Berubicin is the company’s novel anthracycline candidate for the treatment of a number…

FridayFeb 12, 2021 3:20 pm

CNS Pharmaceuticals (NASDAQ: CNSP) Celebrates IND Status, Prepares to Launch Brain Cancer Drug Trials

Brain cancer drug developer CNS Pharmaceuticals is celebrating recent news that the U.S. Food and Drug Administration (“FDA”) granted investigational new drug (“IND”) status to CNS Pharmaceuticals’ leading candidate for fighting glioblastomas Glioblastomas are a class of aggressive brain cancers with no known cure and a median life expectancy of 14 to 16 months following diagnosis The FDA’s decision to grant CNSP’s request for IND status clears the way for the company to begin human clinical trials within the next couple of months The company’s sublicensee partner, WPD Pharmaceuticals, will also prepare a first-ever Phase I trial for drug safety…

ThursdayFeb 04, 2021 3:00 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) on the Verge of Changing History with Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, has set sights on an encouraging future for glioblastoma patients with its upcoming Phase 2 trial of Berubicin. The article detailing this groundbreaking news quoted the company’s CEO John Climaco as saying, “Anthracyclines as a class of chemotherapy have been used for over 60 years to treat a variety of cancers… However, historically, anthracyclines have never been used to treat primary or metastatic brain cancers because scientists could not demonstrate that anthracyclines were able…

WednesdayJan 27, 2021 3:45 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Discusses Product Pipeline, Clinical Trial Plans, at H.C. Wainwright Bioconnect 2021 Virtual Conference

Company will initiate a Phase II adult trial for Berubicin this year focused on patients with glioblastoma multiforme WPD, a CNS sub-license partner, will be commencing a parallel Phase II adult trial and the first-ever pediatric Berubicin trial Additional clinical trials are in the pipeline, including one for the company’s newest drug candidate, WP1244, and its effects on central nervous system tumors Biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) recently took part in the H.C. Wainwright Bioconnect 2021 Virtual Conference, which took place January 11-14, 2021. CNS’s CEO John Climaco gave a presentation at the event, discussing how the clinical-stage biopharmaceutical…

WednesdayJan 13, 2021 12:13 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moving Forward with New Berubicin Clinical Trials, Determined to Help Address Unmet Needs of GBM Patients

IND approval from the FDA has given CNS Pharmaceuticals the green light needed to continue with clinical research of Berubicin in patients suffering from GBM and other brain/nervous system cancers Company holds the exclusive worldwide license for Berubicin, the first anthracycline to cross the blood-brain barrier in the adult brain The GBM therapeutics market is expected to increase to an estimated $3.3 billion in 2024 CNS Pharmaceuticals’ sublicensee will be conducting the first pediatric study using Berubicin CNS Pharmaceuticals (NASDAQ: CNSP) is a clinical-stage biotechnology company that is currently specializing in the development of novel treatments for primary and metastatic…

WednesdayJan 13, 2021 9:46 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Appears on C3 Chat Show Podcast

CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent C3 Chat Show Podcast. The podcast, hosted by Sid Vaidya and Eric Gershey, explores topics related to entrepreneurship, life experiences and best practices. During his interview, Climaco shared the history of CNS Pharmaceuticals and provided an update on the company’s recent business progress, including the fact that the company recently received FDA approval to begin clinical trials studying the company’s lead drug candidate, Berubicin. CNSP is developing Berubicin as a potential treatment for glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. Climaco called Berubicin…

ThursdayJan 07, 2021 9:45 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at the H.C. Wainwright BioConnect 2021 Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its CEO, John Climaco, will present at the virtual H.C. Wainwright BioConnect 2021 Conference. The event is slated to be held from Jan. 11-14, 2021, with Climaco’s presentation scheduled for 6:00 a.m. ET on the first day of the event. Interested parties should visit https://ibn.fm/09lxu to register. The webcast will be available on demand starting at 6:00 a.m. ET on Monday, Jan. 11, 2021. Replays of the presentation will be available…

MondayJan 04, 2021 2:06 pm

CNS Pharmaceuticals (NASDAQ: CNSP) Conducts Public Offering Funding Effort, Appears in Syndicated Broadcast on Brain Cancer Drug Advances

Neuro-oncology drug developer CNS Pharmaceuticals is completing an underwritten public offering of common stock shares and warrants in a bid to fund its upcoming Phase 2 trials for a candidate in fighting glioblastoma brain cancers CNS’s Phase 2 trials are scheduled to begin during Q1 of 2021, building on a Phase 1 trial in which 44 percent of patients saw improvement and one patient has survived cancer-free for nearly 15 years The company has designed an ambitious, adaptive trial that allows for an interim analysis of data and adjustments for efficiency in bringing the drug candidate, Berubicin, to hoped-for approval…

TuesdayDec 29, 2020 11:42 am

Hour of Truth Approaching in CNS Pharmaceuticals (NASDAQ: CNSP) Testing of Drug Candidate Against Deadly Brain Cancer

A novel anthracycline believed to be effective in combatting deadly glioblastoma brain cancers by crossing the blood-brain barrier and zeroing in on the tumor will begin Phase 2 trials during Q1 of next year The drug, Berubicin, is being developed by CNS Pharmaceuticals after initial testing nearly 15 years ago resulted in improvements among some subjects, including one who has survived cancer-free since that time The company, in collaboration with Polish sub-licensee partner WPD Pharmaceuticals, plans a multinational staged series of trials that will attempt to keep time and costs to outcome at a minimum As part of the effort,…

Site Search

Company Search

Tag: CNS Pharmaceuticals Inc. CNSP